ASSESSMENT OF THE QUALITY OF LIFE OF PATIENTS WITH LUNG CANCER IN THE ABAY REGION
Background and Objectives. Lung cancer is the leading cause of cancer-related mortality worldwide. Due to late-stage diagnosis, the five-year survival rate remains as low as 15%. Disease progression, symptom severity, and treatment-related adverse effects significantly diminish the quality of life (QoL) in these patients. The objective of this study was to assess the quality of life in patients with lung cancer.
Materials and Methods. This prospective study was conducted from May to October 2024 in the Abay region of the Republic of Kazakhstan and included 123 patients diagnosed with lung cancer. Patient-reported quality of life and symptom burden were evaluated using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), with scores ranging from 0 to 100.
Results. Overall quality of life (mean score > 50) and functional scales (mean score > 50) were moderate to good. The highest mean score was observed for social functioning (94±11.3), followed by physical functioning (79.73±13.3), cognitive functioning (76.15±19.5), emotional functioning (74.08±22.6), and role functioning (67±15.4).
Conclusions. This study highlights the necessity of conducting multicenter research to assess quality of life in larger populations of lung cancer patients. It underscores that patient-reported outcomes regarding quality of life should be considered essential in developing new healthcare strategies aimed at improving medical care, including treatment, rehabilitation, and palliative support for oncology patients.
Shynggys Adilgazyuly – PhD student of the Department of Public Health, NCJSC "Semey Medical University", Semey, Republic of Kazakhstan, num: +7 777 006 7525, e-mail: shyngys.aa@mail.ru, https://orcid.org/0009-0000-8930-0269;
Tolkyn Bulegenov - Professor of the Department of Hospital and Pediatric Surgery, NCJSC «Semey Medical University», Semey, Republic of Kazakhstan, https://orcid.org/0000-0001-6145-9649; e-mail: tolkynbul@mail.ru;
Akmaral Mussakhanova - associate Professor of the Department of public health and management, NCJSC « Astana Medical University», Astana, Republic of Kazakhstan https://orcid.org/0000-0002-0399-5045, e-mail: makmaral1@gmail.com;
Zhannur Altybayeva - chemotherapy doctor, Center for Nuclear Medicine and Oncology. Semey, Republic of Kazakhstan, https://orcid.org/0009-0005-6632-2808; e-mail: zhan_alt@mail.ru;
Aigul Medeulova - PhD, head of the Department of Otolaryngology, NJSC «Kazakh National Medical University named after S.D. Asfendiyarov», Almaty, Republic of Kazakhstan https://orcid.org/0000-0001-6941-4525, num:+77014217765;
Zhannur Tokenova - assistant, NCJSC "Semey Medical University", Semey, Republic of Kazakhstan; https://orсid 009-0000-4436-279.
Nailya Urazalina - Associate Professor, Candidate of Medical Sciences, Department of Physiological Disciplines named after T.A. Nazarova, NCJSC "Semey Medical University", Semey, Republic of Kazakhstan, https://orсid/0000-0003-0200-1763; e-mail: hakim_15@mail.ru; num: +77779075589.
1. Официальный информационный ресурс Премьер-министра Республики Казахстан «В Казахстане за последние 20 лет смертность от онкологических заболеваний снизилась на 33%». Available from: http: https://primeminister.kz/ru/news/v-kazakhstane-za-poslednie-20-let-smertnost-ot-onkologicheskikh-zabolevaniy-snizilas-na-33-23189.
2. Миллер С.В., Чойнзонов Е.Л., Балацкая Л.Н., Евтушенко В.А., Рудык Ю.В., Завьялов А.А. Оценка качества жизни больныx раком легкого после комбинированного лечения. Сибирский онкологический журнал. 2003; 3 (7): C.3–6. https://cyberleninka.ru/article/n/otsenka-kachestva-zhizni-bolnyh-rakom-legkogo-posle-kombinirovannogo-lecheniya
3. Basch E., Iasonos A., McDonough T., Barz A., Culkin A., Kris M.G., Scher H.I., Schrag D. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. Lancet Oncol. 2006, 7, 903–909.
4. Bjordal K., de Graeff A., Fayers P.M., Hammerlid E., van Pottelsberghe C., Curran D., Ahlner-Elmqvist M., Maher E.J., Meyza J.W., Bredart A. et al. A 12-country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur. J. Cancer 2000, 36, 1796–1807.
5. Bordoni R., Ciardiello F., von Pawel J., Cortinovis D. He P., Karagiannis T., Ballinger M., Sandler A., Yu W., Felizzi F. et al. P1.01-052 Patient reported outcomes (PROs) in OAK: A phase III study of atezolizumab vs docetaxel in non-small-cell lung cancer (NSCLC). J. Thorac Oncol. 2017, 12, S1914–S1915.
6. Borghaei H., Paz-Ares L., Horn L., Spigel D.R., Steins M., Ready N.E., Chow L.Q., Vokes E.E., Felip E., Holgado E. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 2015, 373, 1627–1639.
7. Brahmer J., Reckamp K.L., Baas P., Crino L., Eberhardt W.E., Podduskaya E., Antonia S., Pluzanski A., Vokes E.E., Holgado E. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 2015, 373, 123–135.
8. Bray F., Ferlay J., Soerjomataram I., Siegel R., Torre L., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018, 68, 394–424.
9. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R., Soerjomataram I., Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74, 229–263.
10. Carbone D.P., Reck M., Paz-Ares L., Creelan B., Horn L. et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 2017, 376, 2415–2426.
11. Chi S.A., Yu H., Choi Y., Park S., Sun J.M. et al. Trends in Survival Rates of Non–Small Cell Lung Cancer with Use of Molecular Testing and Targeted Therapy in Korea, 2010–2020. JAMA Netw. Open 2023, 6, e232002.
12. Damm K., Roeske N., Jacob C. Health-related quality of life questionnaires in lung cancer trials: A systematic literature review. Health Econ. Rev. 2013, 3, 15.
13. Fehrenbacher L., Spira A., Ballinger M., Kowanetz M., Vansteenkiste J., Mazieres J., Park K., Smith D., Artal-Cortes A., Lewanski C. et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicenter, open-label, phase 2 randomised controlled trial. Lancet 2016, 387, 1837–1846.
14. Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Pineros M., Znaor A., Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 2019, 144, 1941–1953.
15. Ganti A., Klein A., Cotarla I., Seal B., Chou E. Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients with Non-Small Cell Lung Cancer in the US. JAMA Oncol. 2021, 7, 1824–1832.
16. Herbst R.S., Baas P., Kim D.W., Felip E., Perez-Gracia J.L. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016, 387, 1540–1550.
17. Hopwood P., Stephens R.J. Depression in patients with lung cancer: Prevalence and risk factors derived from quality-of-life data. J. Clin. Oncol. 2000, 18, 893–903.
18. Hong Y., Park S., Lee M.K. The prognosis of non-small cell lung cancer patients according to endobronchial metastatic lesion. Sci. Rep. 2022, 12, 13588.
19. Lee, J.L.; Jeong, Y. Quality of life in patients with non-small cell lung cancer: Structure Equation Modeling. Cancer Nurs. 2019, 42, 475–483
20. Lemonnier, I., Guillemin F.; Arveux, P.; Clément-Duchêne C. et al. Quality of Life after the Initial Treatments of Non-Small Cell Lung Cancer: A Persistent Predictor for Patients’ Survival. Health Qual. Life Outcomes 2014, 12, 73.
21. Langer C.J., Gadgeel S.M., Borghaei H., Papadimitrakopoulou V.A., Patnaik A., Powell F.S., Gentzler R.D., Martins R.G., Stevenson J.P., Jalal S.I. et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced non-squamous non-small-cell lung cancer: A randomized, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016, 17, 1497–1508.
22. Larsson M., Ljung L., Johansson B. Health-related quality of life in advanced non-small cell lung cancer: Correlates and comparisons to normative data. Eur. J. Cancer Care 2012, 21, 642–649.
23. McKenna S.P. Measuring patient-reported outcomes: Moving beyond misplaced common sense to hard science. BMC Med. 2011, 9, 86.
24. Reck M., Taylor F., Penrod J.R., DeRosa, M., Morrissey L., Dastani H., Orsini L., Gralla R.J. Impact of nivolumab versus docetaxel on health-related quality of life and symptoms in patients with advanced squamous non-small cell lung cancer: Results from the CheckMate 017 study. J. ThoracOncol. 2018, 13, 194–204.
25. Rittmeyer A., Barlesi F., Waterkamp D., Park K., Ciardiello F., von Pawel J., Gadgeel S.M., Hida T., Kowalski D.M., Dols M.C. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicenter randomised controlled trial. Lancet 2017, 389, 255–265.
26. Siddiqui F., Kohl R., Swann S., Watkins-Bruner, D., Movsas B. Gender differences in pretreatment quality of life in a prospective lung cancer trial. J. Support. Oncol. 2008, 6, 33–39.
27. Stylianou C., Kalemikerakis I., Konstantinidis T., Kafazi A., Alevizopoulos N., Parissopoulos S., Govina O. Quality of Life and Symptom Burden in Non-Small-Cell Lung Cancer Patients Receiving Second-Line Chemotherapy Compared with Immunotherapy. Medicina 2024, 60, 1845. https://doi.org/10.3390/medicina60111845
28. Van derWeijst L., Surmont V., Schrauwen, W., Lievens Y. Systematic literature review of health-related quality of life in locally-advanced non-small cell lung cancer: Has it yet become state-of-the-art? Crit. Rev. Oncol. Hematol. 2017, 119, 40–49.
Количество просмотров: 239
Категория статей:
Оригинальное исследование
Библиографическая ссылка
Adilgazyuly Sh., Bulegenov T., Mussakhanova A., Altybayeva Zh., Medeulova A., Tokenova Zh., Urazalina N.M. Assessment of the quality of life of patients with lung cancer in the Abay region // Nauka i Zdravookhranenie [Science & Healthcare]. 2025. Vol.27 (1), pp. 26-31. doi 10.34689/SH.2024.27.1.003Похожие публикации:
VIRAL HEPATITIS IN KAZAKHSTAN: REGIONAL EPIDEMIOLOGICAL OVERVIEW
PREDICTORS OF ANTIVIRAL THERAPY INEFFECTIVENESS IN CHRONIC HEPATITIS C: A MATCHED CASE-CONTROL STUDY IN ALMATY, A MAJOR METROPOLIS OF KAZAKHSTAN
МЕДИКО – СОЦИАЛЬНЫЕ ОСОБЕННОСТИ ПРИВЕРЖЕННОСТИ К ЛЕЧЕНИЮ БОЛЬНЫХ С ХРОНИЧЕСКИМ ПАНКРЕАТИТОМ
PATHOGENETIC ASSESSMENT OF CLINICAL AND INSTRUMENTAL PARAMETERS OF THE LUNGS IN PATIENTS WITH DIABETES MELLITUS
ANTIBIOTIC RESISTANCE OF STAPHYLOCOCCUS AUREUS TO VARIOUS CLINICAL BIOMATERIALS: A COMPARATIVE ANALYSIS